Authors
Latest:
CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through AccountabilityAlthough the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.
Latest:
Dr Sinno on Molecular Characterization in Endometrial CancerAbdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.
Latest:
FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhDDrs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.
Latest:
Dr. Zauderer on the Importance of Optimizing Care in MesotheliomaMarjorie G. Zauderer, MD, discusses the importance of optimizing care for patients with mesothelioma.
Latest:
Dr Feldman on the Recognition of Racial Disparities in Breast CancerSheldon M. Feldman, MD, discusses the recognition of racial disparities in breast cancer, as well as the mitigation of treatment-related toxicities.
Latest:
JAK Inhibitors Continue to Shape the Treatment Landscape of MyelofibrosisFollowing the FDA approvals of the JAK inhibitors ruxolitinib, fedratinib, and pacritinib, the treatment landscape of myelofibrosis continues to grow with the use of these agents with an additional FDA review planned for momelotinib in September 2023.
Latest:
Dr Stintzing on the Safety Profile of Fruquintinib in mCRCSebastian Stintzing, MD, discusses the Q-TWiST analysis of fruquintinib plus best supportive care in metastatic colorectal cancer.
Latest:
Dr Katims on the Feasibility of scRNA-seq in FGFR3+ Upper Tract Urothelial CarcinomaAndrew Katims, MD, MPH, discusses the feasibility of using single-cell RNA-sequencing in FGFR3-mutated upper tract urothelial carcinoma
Latest:
Dr Hoppe on Outcomes of the CheckMate 744 Trial in Hodgkin LymphomaBradford (Brad) S. Hoppe, MD, MPH, discusses the rationale for investigating consolidative radiotherapy in place of autologous stem cell transplant in patients with low-risk, relapsed/refractory classic Hodgkin lymphoma who have been previously treated with nivolumab plus brentuximab vedotin, as investigated in the phase 2 CheckMate 744 study, as well as key findings from this trial.
Latest:
Dr Ryan on the Role of Adjuvant Therapy in RCCChristopher W. Ryan, MD, discusses the role of adjuvant therapy for patients with renal cell carcinoma.
Latest:
Dr Winter on Unmet Needs in Richter Transformation for Patients With CLLAllison Winter, MD, discusses unmet needs for patients with Richter transformation from CLL.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Dr Blanco on Unmet Needs for Pediatric Patients With Relapsed Brain TumorsJezabel Rodriguez-Blanco, PhD, discusses unmet needs for pediatric patients with relapsed brain tumors, including the need for additional treatment approaches for these patients.
Latest:
Dr. Simons on Racial Disparities Reported in Luminal Breast CancerYael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.
Latest:
Fox Chase Cancer Center Welcomes Dr Eric GoodlevEric Goodlev, MD, has joined Fox Chase Cancer Center as an associate Professor in the Supportive Oncology and Palliative Care Program.
Latest:
Kelsen on DEI Initiatives at Columbia University in Patients With CancerMoshe Kelsen, MBA, discusses ongoing initiatives that aim to improve diversity, equity, and inclusion for patients with cancer receiving treatment at Columbia University.
Latest:
Dr Pistilli on Understanding Dynamic HER2 Expression in Metastatic Breast CancerBarbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.
Latest:
Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast CancerBhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.
Latest:
Dr. Tsai on Ongoing Research Efforts in Pancreatic CancerSusan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer.
Latest:
Survey Aims to Identify COVID-19–Related Health Care Challenges in Latin AmericaOutbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.
Latest:
Dr Lim on the Significance of the FDA Approval of Adjuvant Ribociclib in HR+/HER2– Breast CancerBora Lim, MD, discusses the FDA approval of adjuvant ribociclib plus an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular LymphomaLoretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.
Latest:
Dr Harpole on the Design of an Exploratory Analysis of the AEGEAN Trial in NSCLCDavid Harpole, MD, discusses on the rationale and design of an exploratory analysis of the phase 3 AEGEAN trial in patients with EGFR-mutated non–small cell lung cancer, which he presented at the 2023 IASLC World Conference on Lung Cancer.
Latest:
Second-Line Treatment of SCLCVamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.
Latest:
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate CancerAngela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.
Latest:
Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast CancerKo Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.
Latest:
Renal Cell Carcinoma: Future Evolutions in CareShared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.
Latest:
EGFR+ NSCLC: Advice for Community OncologistsA panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Latest:
Dr Shields on Incorporating Tarlatamab into Clinical Practice for ES-SCLCMisty D. Shields, MD, PhD, discusses the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.
Latest:
Scientists Create Nanoparticle That Helps Fight Solid TumorsResearchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.
.jpg?fit=crop&auto=format)
